Quick Links
Top Searched Items
Advanced Business Search
Incredibly rare opportunity to own two JM submarine sandwich shops. Highly respected and popular brand. Stores are in and around City of Industry, LA County. 2017 gross $1,218,165, 2018 gross $1,246,462.. Each store is cash flow positive. 2018 SDE $77,549. Priced to sell now at $349,500 for both! SBA Possible.Stores have been absentee owned but not recommended. Transitioning buyer can step into this startup/turnaround operation without the financial and time investment required to launch from scratch. New So. CA franchises are currently requiring an investment of about $400k per store to launch new plus at least 6 months to identify location, negotiate leases, tenant improvement/build out, recruiting, hiring and training - just to get the doors open.Move in ready (approx.2&4 years new). Originally 20 year leases including the renewal options on 1100 and 1200 sqft respectively. Solid locations. New office complex is adding 1000 potential customers across from one of the stores this year. Hwy construction near the other will complete soon streamlining traffic flow into the center.LA territories are otherwise sold out! Opportunities for additonal stores once you are 'in the system' but no other way to enter the JM system in LA from 'the outside'.22-24 employees, 6 key holders. FFE estimated at $80k, Approximately $20k inventory. FFE available for purchase for 3rd store (currently in storage) - $25k.Stores are positioned for significant growth with appropriate owner operator focus on catering, delivery and foot traffic. As few as 25 additional sandwich sales per store per day will make a significant impact on profitability (all profit less COGS). As profitability improves, price will increase so serious buyers should not wait.Seller motivated as family has other business interests. Serious inquiries from those prepared to act immediately will be prioritized.
California Licensed Non-Medical In-Home Care-Life Care Management company.This company was founded in 2009. Company has specialized in the total care oversight of frail older adults. Service offerings have included: Life Care Management, Non-medical Home Care Aides and Referral and placement.Care Management includes; assessment and care planning, on-going care coordination by touching the physical, mental, social and spiritual needs of clients. The life care manager serves as liaison and advocate between the client, family and healthcare providers.Non-Medical Home Care Aides: Offers both companion and personal care services in the client home. Services range from light housekeeping, errands, meal preparation to hands on assistance. Which includes activities of daily living such as grooming and hygiene to full end of life care. The care aides can service can range from 2-3 hours to 24 hour live in care.Referral and Placement: Referral fee paid by contracted retirement living facilities. This is a Free service to assist clients and families in securing suitable retirement living which is customized to their individual needs. Currently 13 clients are receiving inhome care. In addition, the company has 13 active field employees others available as needed. Owner works full time in the business and wants to explore other opportunities.Appropriate for home based operation (assuming a 3rd party office for occasional meetings) or fold into existing operation. This is not appropriate for individuals not already experienced in the business.Projected 2019 Revenue $700k, potential earnings $150k (assumes home based with owner - operator). Company restructured early 2019 so historic data, though available is no longer relevant. Asking Price is $199,000.
Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.
The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500,000 to $1MM to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
Absentee-run business owners wanted for Managed & Operated Oil & Gas Properties, Land Leases, Production, Monthly Revenue, and Enhanced Oil Recovery. Absentee owners, let your money work for you by a professionally operated company. Owner opportunities from $50,000 to $50,000,000 backed by years of industry experience. Project design available for projects customized to suit your financial and risk tolerance. Current lease ready to produce with five to nine million barrels of oil in place (proven reserves) Nitrogen, microbe, saltwater injection, and recovery. Turn $5.5 million into $100 million. Opportunities in Texas and Oklahoma, Louisiana. Permian Basin, Wilcox, Wolf camp, Canyon Sand, Clear Fork, San Andres, and many more highly sought-after formations. Now is the time to act! Oil prices are on the rise, projections are as high as $200 per barrel! Don't miss the ride!
Okay
Please Confirm
Are you sure you wish to REMOVE from your request basket?
Save Your Search Results
If you have listings on our site or you have a Listings By Email account, you can use your same login credentials below. Log in to your account to save your search(es).
Create your FREE Listings By Email Account
Simply enter your email address for your account. Once verified, your password will be immediately sent to you at this email address.
Password reset link has been sent out, you can click and create a new password.
We're Sorry
We only allow businesses per information request. Please complete your current requests to continue.
Complete Requests »
Oops!
Wow, glad you're interested in so many businesses! The you've inquired to will contact you shortly.
Sounds Good
Learn how you can create the life you want. Small business financing with Guidant Financial
Business Funding From Guidant Financial
Thank you for Business Funding Pre-Qualification Request.
You should receive an email response within a hour
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.
